Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2022

Open Access 01-12-2022 | Knee Osteoarthritis | Research

Possible synergic action of non-steroidal anti-inflammatory drugs and glucosamine sulfate for the treatment of knee osteoarthritis: a scoping review

Authors: Nicola Veronese, Fiona Ecarnot, Sara Cheleschi, Antonella Fioravanti, Stefania Maggi

Published in: BMC Musculoskeletal Disorders | Issue 1/2022

Login to get access

Abstract

Background

Several studies have reported that glucosamine sulfate (GS) can improve knee osteoarthritis (OA) symptomatology. In parallel, the disease-modifying effects of non-steroidal anti-inflammatory drugs (NSAIDs) in knee OA have also been investigated. However, limited literature has reported the combined effect of GS and NSAIDs. The aim of this scoping review is to describe the scope and volume of the literature investigating the potential benefits and synergistic effect of a combination of GS and NSAIDs in patients with knee OA.

Methods

PubMed and Embase were searched for studies published from inception through April 2022, evaluating the effects of the combination of GS and NSAIDs in OA patients, versus either treatment alone. Data are reported narratively.

Results

Five studies were included in this review; 4 were randomized control trials and one was a prospective observational study. The duration of combination treatment was 6 to 12 weeks. The combination was compared to celecoxib in 2 studies, meloxicam in 1, etoricoxib in 1, and a conventional NSAID in 1 (ibuprofen or piroxicam). All 5 studies reported that in patients with knee OA, the combination of GS plus NSAID yielded a significantly greater benefit than single-agent therapy, in terms of outcomes including pain reduction, function, joint stiffness, and markers of inflammatory activity and cartilage degradation.

Conclusion

The 5 studies included in this scoping review all report a significantly greater clinical benefit with a combination of GS plus NSAID compared to either treatment alone. The evidence supports efficacy in reducing pain, improving function, and possibly regulating joint damage. However, further randomized trials with larger sample sizes are warranted to confirm these findings.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Tenti S, et al. Impact of thumb osteoarthritis on pain, function, and quality of life: a comparative study between erosive and non-erosive hand osteoarthritis. Clin Rheumatol. 2020;39:2195–206.CrossRef Tenti S, et al. Impact of thumb osteoarthritis on pain, function, and quality of life: a comparative study between erosive and non-erosive hand osteoarthritis. Clin Rheumatol. 2020;39:2195–206.CrossRef
3.
go back to reference Long H, et al. Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019. Arthritis Rheumatol. 2022;74:1172–83.CrossRef Long H, et al. Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019. Arthritis Rheumatol. 2022;74:1172–83.CrossRef
4.
go back to reference Arden NK, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17:59–66.CrossRef Arden NK, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17:59–66.CrossRef
5.
go back to reference Bruyere O, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337–50.CrossRef Bruyere O, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337–50.CrossRef
6.
go back to reference Brophy RH, Fillingham YA. AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition. J Am Acad Orthop Surg. 2022;30:e721–9.CrossRef Brophy RH, Fillingham YA. AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition. J Am Acad Orthop Surg. 2022;30:e721–9.CrossRef
7.
go back to reference Kolasinski SL, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72:220–33.CrossRef Kolasinski SL, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72:220–33.CrossRef
8.
go back to reference Birch S, Lee MS, Robinson N, Alraek T, The UKNICE. Guidelines for Osteoarthritis of the Knee: Lessons Learned in a Narrative Review Addressing Inadvertent Limitations and Bias. J Altern Complement Med. 2014;2017(23):242–6. Birch S, Lee MS, Robinson N, Alraek T, The UKNICE. Guidelines for Osteoarthritis of the Knee: Lessons Learned in a Narrative Review Addressing Inadvertent Limitations and Bias. J Altern Complement Med. 2014;2017(23):242–6.
9.
go back to reference Bannuru RR, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27:1578–89.CrossRef Bannuru RR, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27:1578–89.CrossRef
10.
go back to reference Leopoldino AO, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019;2:CD013273. Leopoldino AO, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019;2:CD013273.
11.
go back to reference Aweid O, Haider Z, Saed A, Kalairajah Y. Treatment modalities for hip and knee osteoarthritis: A systematic review of safety. J Orthop Surg (Hong Kong). 2018;26:2309499018808669.CrossRef Aweid O, Haider Z, Saed A, Kalairajah Y. Treatment modalities for hip and knee osteoarthritis: A systematic review of safety. J Orthop Surg (Hong Kong). 2018;26:2309499018808669.CrossRef
12.
go back to reference Colletti A, Cicero AFG. Nutraceutical approach to chronic osteoarthritis: from molecular research to clinical evidence. Int J Mol Sci. 2021;22:12920.CrossRef Colletti A, Cicero AFG. Nutraceutical approach to chronic osteoarthritis: from molecular research to clinical evidence. Int J Mol Sci. 2021;22:12920.CrossRef
13.
go back to reference Chiu HW, et al. Glucosamine inhibits IL-1beta expression by preserving mitochondrial integrity and disrupting assembly of the NLRP3 inflammasome. Sci Rep. 2019;9:5603.CrossRef Chiu HW, et al. Glucosamine inhibits IL-1beta expression by preserving mitochondrial integrity and disrupting assembly of the NLRP3 inflammasome. Sci Rep. 2019;9:5603.CrossRef
14.
go back to reference Mousavi SH, Bakhtiari E, Hosseini A, Jamialahmadi K. Protective effects of glucosamine and its acetylated derivative on serum/glucose deprivation-induced PC12 cells death: Role of reactive oxygen species. Res Pharm Sci. 2018;13:121–9.CrossRef Mousavi SH, Bakhtiari E, Hosseini A, Jamialahmadi K. Protective effects of glucosamine and its acetylated derivative on serum/glucose deprivation-induced PC12 cells death: Role of reactive oxygen species. Res Pharm Sci. 2018;13:121–9.CrossRef
15.
go back to reference Shmagel A, et al. The effects of glucosamine and chondroitin sulfate on gut microbial composition: a systematic review of evidence from animal and human studies. Nutrients. 2019;11:294.CrossRef Shmagel A, et al. The effects of glucosamine and chondroitin sulfate on gut microbial composition: a systematic review of evidence from animal and human studies. Nutrients. 2019;11:294.CrossRef
16.
go back to reference Jordan KM, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–55.CrossRef Jordan KM, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–55.CrossRef
17.
go back to reference Obeid S, et al. Cardiorenal risk of celecoxib compared to naproxen, or ibuprofen in arthritis patients: insights from the PRECISION trial. Eur Heart J Cardiovasc Pharmacother. 2022;8:611.CrossRef Obeid S, et al. Cardiorenal risk of celecoxib compared to naproxen, or ibuprofen in arthritis patients: insights from the PRECISION trial. Eur Heart J Cardiovasc Pharmacother. 2022;8:611.CrossRef
18.
go back to reference Chan FK, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376:173–9.CrossRef Chan FK, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376:173–9.CrossRef
19.
go back to reference Zweers MC, et al. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther. 2011;13:239.CrossRef Zweers MC, et al. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther. 2011;13:239.CrossRef
20.
go back to reference Nakata K, et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2018;26:1263–73.CrossRef Nakata K, et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2018;26:1263–73.CrossRef
21.
go back to reference Fioravanti A, et al. In vitro effects of VA441, a new selective cyclooxygenase-2 inhibitor, on human osteoarthritic chondrocytes exposed to IL-1beta. J Pharmacol Sci. 2012;120:6–14.CrossRef Fioravanti A, et al. In vitro effects of VA441, a new selective cyclooxygenase-2 inhibitor, on human osteoarthritic chondrocytes exposed to IL-1beta. J Pharmacol Sci. 2012;120:6–14.CrossRef
22.
go back to reference Timur UT, et al. Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review. Int J Mol Sci. 2020;21:6962.CrossRef Timur UT, et al. Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review. Int J Mol Sci. 2020;21:6962.CrossRef
23.
go back to reference Matsuda K, Nakamura S, Matsushita T. Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints. Rheumatol Int. 2006;26:991–5.CrossRef Matsuda K, Nakamura S, Matsushita T. Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints. Rheumatol Int. 2006;26:991–5.CrossRef
24.
go back to reference Ou Y, et al. Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte. Med Sci Monit. 2012;18:BR247-252.CrossRef Ou Y, et al. Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte. Med Sci Monit. 2012;18:BR247-252.CrossRef
25.
go back to reference Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther. 2006;8:R2.CrossRef Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther. 2006;8:R2.CrossRef
26.
go back to reference Cheleschi S, et al. A combination of celecoxib and glucosamine sulfate has anti-inflammatory and chondroprotective effects: results from an in vitro study on human osteoarthritic chondrocytes. Int J Mol Sci. 2021;22:8980.CrossRef Cheleschi S, et al. A combination of celecoxib and glucosamine sulfate has anti-inflammatory and chondroprotective effects: results from an in vitro study on human osteoarthritic chondrocytes. Int J Mol Sci. 2021;22:8980.CrossRef
27.
go back to reference Munn Z, et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18:143.CrossRef Munn Z, et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18:143.CrossRef
28.
go back to reference Pham MT, et al. A scoping review of scoping reviews: advancing the approach and enhancing the consistency. Res Synth Methods. 2014;5:371–85.CrossRef Pham MT, et al. A scoping review of scoping reviews: advancing the approach and enhancing the consistency. Res Synth Methods. 2014;5:371–85.CrossRef
29.
go back to reference Amuzadeh F, et al. Comparison of the efficacy of combination of glucosamine sulfate and celecoxib versus celecoxib alone for the pain, morning stiffness, function relief of females with osteoarthritis grade 1&2 of the knee (A comparative study). Indian J Fundam Appl Life Sci. 2015;5:129–36. Amuzadeh F, et al. Comparison of the efficacy of combination of glucosamine sulfate and celecoxib versus celecoxib alone for the pain, morning stiffness, function relief of females with osteoarthritis grade 1&2 of the knee (A comparative study). Indian J Fundam Appl Life Sci. 2015;5:129–36.
30.
go back to reference Lu Z, et al. Therapeutic effects of combined meloxicam and glucosamine sulfate treatment on patients with osteoarthritis, and its effect on serum CTX-I, CTX-II, COMP and MMP-3. Trop J Pharm Res. 2019;18:1553–7. Lu Z, et al. Therapeutic effects of combined meloxicam and glucosamine sulfate treatment on patients with osteoarthritis, and its effect on serum CTX-I, CTX-II, COMP and MMP-3. Trop J Pharm Res. 2019;18:1553–7.
31.
go back to reference Deng G, Chen X, Yang K, Wu A, Zeng G. Combined effect of celecoxib and glucosamine sulfate on inflammatory factors and oxidative stress indicators in patients with knee osteoarthritis. Trop J Pharm Res. 2019;18:397–402.CrossRef Deng G, Chen X, Yang K, Wu A, Zeng G. Combined effect of celecoxib and glucosamine sulfate on inflammatory factors and oxidative stress indicators in patients with knee osteoarthritis. Trop J Pharm Res. 2019;18:397–402.CrossRef
32.
go back to reference Sun Y, Wang C, Gong C. Repairing effects of glucosamine sulfate in combination with etoricoxib on articular cartilages of patients with knee osteoarthritis. J Orthop Surg Res. 2020;15:150.CrossRef Sun Y, Wang C, Gong C. Repairing effects of glucosamine sulfate in combination with etoricoxib on articular cartilages of patients with knee osteoarthritis. J Orthop Surg Res. 2020;15:150.CrossRef
33.
go back to reference Selvan T, Rajiah K, Nainar MS, Mathew EM. A clinical study on glucosamine sulfate versus combination of glucosamine sulfate and NSAIDs in mild to moderate knee osteoarthritis. Sci World J. 2012;2012:902676.CrossRef Selvan T, Rajiah K, Nainar MS, Mathew EM. A clinical study on glucosamine sulfate versus combination of glucosamine sulfate and NSAIDs in mild to moderate knee osteoarthritis. Sci World J. 2012;2012:902676.CrossRef
34.
go back to reference Conaghan PG, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford). 2015;54:270–7.CrossRef Conaghan PG, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford). 2015;54:270–7.CrossRef
35.
go back to reference Yeap SS, et al. 2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. Aging Clin Exp Res. 2021;33:1149–56.CrossRef Yeap SS, et al. 2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. Aging Clin Exp Res. 2021;33:1149–56.CrossRef
36.
go back to reference Zhang Z, et al. 2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint. Aging Clin Exp Res. 2021;33:2141–7.CrossRef Zhang Z, et al. 2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint. Aging Clin Exp Res. 2021;33:2141–7.CrossRef
37.
go back to reference Yeap SS, et al. A Malaysian Delphi consensus on managing knee osteoarthritis. BMC Musculoskelet Disord. 2021;22:514.CrossRef Yeap SS, et al. A Malaysian Delphi consensus on managing knee osteoarthritis. BMC Musculoskelet Disord. 2021;22:514.CrossRef
38.
go back to reference Pradelli L, et al. Non-Surgical Treatment of Knee Osteoarthritis: Multidisciplinary Italian Consensus on Best Practice. Ther Clin Risk Manag. 2021;17:507–30.CrossRef Pradelli L, et al. Non-Surgical Treatment of Knee Osteoarthritis: Multidisciplinary Italian Consensus on Best Practice. Ther Clin Risk Manag. 2021;17:507–30.CrossRef
39.
go back to reference Gnylorybov AM, et al. Expert Opinion on the Extensive Use of Prescription Crystalline Glucosamine Sulfate in the Multimodal Treatment of Osteoarthritis in Ukraine, Kazakhstan, Uzbekistan, and Armenia. Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1179544120946743.CrossRef Gnylorybov AM, et al. Expert Opinion on the Extensive Use of Prescription Crystalline Glucosamine Sulfate in the Multimodal Treatment of Osteoarthritis in Ukraine, Kazakhstan, Uzbekistan, and Armenia. Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1179544120946743.CrossRef
40.
go back to reference Kucharz EJ, et al. Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis. Rheumatol Int. 2019;39:1117–23.CrossRef Kucharz EJ, et al. Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis. Rheumatol Int. 2019;39:1117–23.CrossRef
41.
go back to reference Alexander LAM, et al. Pharmacological Management of Osteoarthritis With a Focus on Symptomatic Slow-Acting Drugs: Recommendations From Leading Russian Experts. J Clin Rheumatol. 2021;27:e533–9.CrossRef Alexander LAM, et al. Pharmacological Management of Osteoarthritis With a Focus on Symptomatic Slow-Acting Drugs: Recommendations From Leading Russian Experts. J Clin Rheumatol. 2021;27:e533–9.CrossRef
42.
go back to reference Hiligsmann M, et al. Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clin Exp Res. 2019;31:1–3.CrossRef Hiligsmann M, et al. Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clin Exp Res. 2019;31:1–3.CrossRef
43.
go back to reference Turk D, et al. Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. Osteoarthritis Cartilage. 2020;28:1202–13.CrossRef Turk D, et al. Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. Osteoarthritis Cartilage. 2020;28:1202–13.CrossRef
44.
go back to reference Beaudart C, et al. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs. 2020;80:1947–59.CrossRef Beaudart C, et al. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs. 2020;80:1947–59.CrossRef
45.
go back to reference Veronese N, et al. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975927.CrossRef Veronese N, et al. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975927.CrossRef
46.
go back to reference Kucharz EJ, et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin. 2016;32:997–1004.CrossRef Kucharz EJ, et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin. 2016;32:997–1004.CrossRef
Metadata
Title
Possible synergic action of non-steroidal anti-inflammatory drugs and glucosamine sulfate for the treatment of knee osteoarthritis: a scoping review
Authors
Nicola Veronese
Fiona Ecarnot
Sara Cheleschi
Antonella Fioravanti
Stefania Maggi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2022
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-022-06046-6

Other articles of this Issue 1/2022

BMC Musculoskeletal Disorders 1/2022 Go to the issue